Patent 9211263 was granted and assigned to Elcelyx Therapeutics Inc. on December, 2015 by the United States Patent and Trademark Office.
Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.